Prophylactic rhTPO Prevents Cancer Therapy-Induced Thrombocytopenia During Concurrent Chemoradiotherapy in Limited-Stage SCLC:A Prospective, Multicenter, Phase II Clinical Trial - PubMed
4 hours ago
- #chemoradiotherapy
- #thrombocytopenia
- #small-cell lung cancer
- Prophylactic rhTPO prevents cancer therapy-induced thrombocytopenia (CTIT) during concurrent chemoradiotherapy (CCRT) in limited-stage small-cell lung cancer (LS-SCLC).
- A phase II clinical trial across 14 Chinese centers enrolled 56 LS-SCLC patients receiving CCRT with rhTPO (300 IU/kg/day) on specific days.
- Nadir platelet count was 128.54 ± 54.15, and peak platelet count reached 409.23 ± 173.50 during rhTPO treatment.
- Overall CTIT incidence was 33.9%, with 8.9% Grade 3 and no Grade 4-5 events.
- 78.9% of patients with CTIT recovered platelet counts to ≥100 × 10⁹/L during rhTPO treatment, with a median recovery time of 8 days.
- Low baseline platelet count (<150 × 10⁹/L) was an independent risk factor for CTIT (OR = 4.26).
- No patients required platelet transfusions or radiotherapy interruptions, and only one patient needed a chemotherapy dose reduction.
- rhTPO-related adverse reactions were infrequent and mostly Grade 1 (e.g., transient platelet elevation).
- Prophylactic rhTPO demonstrated potential benefits in maintaining platelet counts with low CTIT incidence, supporting further investigation for high-risk patients.